Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Date:2/24/2009

AMSTERDAM, the Netherlands, February 24 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year of 2008.

    Highlights

    - Extra clinical trial in LPL deficiency causes a delay of the announced
      filing date for lead product GlyberaTM which is now expected H2 2009
    - Positive clinical data on GlyberaTM
    - CEO Ronald Lorijn resigned for personal reasons
    - Start of clinical multicenter Hemophilia B trial in 2009
    - Start development of treatments for Duchenne Muscular Dystrophy and
      Parkinson's disease
    - Scale up of unique and proprietary production platform to fully support
      worldwide commercial supply for current products
    - Independent supervisory board with three new members bringing extensive
      knowledge and experience.
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 34.2 million at December 31, 2008

Results comparison

AMT's operating loss increased to EUR 18.8 million for 2008, from EUR 14.7 million for 2007. The difference is primarily due to the increase of research & development costs to EUR 13.1 million, from EUR 9.8 million in 2007. This increase is particularly related to the development work on the company's lead product, GlyberaTM, increased staffing for this and other programs and an increase in research collaborations. General and administrative costs increased to EUR 5.9 million, from EUR 5.0 million in 2007, primarily as a result of increased employee costs and increased advisor's fees. The net loss for 2008 was EUR 16.9 million, as compared to a net loss of EUR 14.9 million for 2007. As of December 31, 2008, AMT had cash and cash equivalents of EUR 34.2 million, compared to EUR 51.3 million at December 31, 2007. The cash burn for the year amounted to EURO 17.2 million which i
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
4. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
10. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
11. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
(Date:8/20/2014)... High performance computing (HPC) will ... complete climate and Earth system model to address ... , Eight national laboratories, including Lawrence Livermore ... for Atmospheric Research, four academic institutions and one ... national laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los ...
(Date:8/20/2014)... Not long ago, it was more or less ... in the development cycle – even after the final ... that, like many things GxP, expectations for early E&L ... drug sponsors have been required by authorities to provide ... I/II. It’s not only clinical trial material containers causing ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Report Represents Major Step in Cancer Genome Research, ... a Beckman Coulter company, announced today that its,Genomic ... released study from,Johns Hopkins Kimmel Cancer Center. The ... the discovery of 200 genes linked to breast ...
... Biosciences Inc. announces the,launch of its SurgiMend(TM) Collagen ... 510(k) clearance from the U.S. Food and Drug,Administration ... and,reconstructive surgery, including breast reconstruction, and for tendon,augmentation, ... and,muscle flap reinforcement indications. "SurgiMend has been ...
... to empower transplant patients ... and ... US,Inc. (Pink Sheets: ALPMF), a leader in the field of ... organization, announced a collaborative partnership to jointly,develop further materials for ...
Cached Biology Technology:Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers 2Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers 3TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
(Date:8/20/2014)... MA Using population-based screening outcomes of approximately 3 ... including four researchers at the University of Massachusetts Medical ... immunodeficiency (SCID) can be successfully implemented across public health ... published in the Aug. 20 issue of the ... ) showed the rate of SCID in newborns is ...
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... for Biodiversity Science (QCBS) cordially invites you to its ... from government, the private sector and NGOs to reflect ... the International Year of Biodiversity. CONFIRMED SPEAKERS TO ... the H. John Heinz III Centre for Science, Economics, ...
... tonnes of carbon dioxide a year from the time food ... more than 20% of total yearly emissions. That is what ... the first time that human excrements contribute to water pollution, ... from the Universidad de Almera (UAL) has estimated the environmental ...
... the University of Illinois at Chicago have been awarded more ... Institute to investigate both the acquired and familial causes of ... diagnosis and targets for cures. The five years of ... John Solaro, distinguished university professor and head of physiology and ...
Cached Biology News:Every person emits 2 tons of CO2 a year through eating 2$12 million grant to probe root causes of heart failure 2
...
... derived from frozen embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 7 ... are large (3-5 mm in diameter) in ...
... cycler is a completely redesigned and updated ... it accepts the full line of well-proven ... precision in thermal performance as the DNA ... allowing easy transport of protocols among platforms. ...
... 2 tube gel adaptors, 24 glass ... gaskets, grommets, stoppers. The PROTEAN II xi ... offer the versatility to perform a variety ... 2-D electrophoresis, native, preparative, and gradient PAGE ...
Biology Products: